{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sathe K"],"funding":["Wellcome Trust"],"pagination":["3336-47"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3501971"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["135(Pt 11)"],"pubmed_abstract":["Parkinson's disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. S100B is a calcium-binding protein expressed in, and secreted by, astrocytes. There is increasing evidence that S100B acts as a cytokine or damage-associated molecular pattern protein not only in inflammatory but also in neurodegenerative diseases. In this study, we show that S100B protein levels were higher in post-mortem substantia nigra of patients with Parkinson's disease compared with control tissue, and cerebrospinal fluid S100B levels were higher in a large cohort of patients with Parkinson's disease compared with controls. Correspondingly, mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine showed upregulated S100B mes"],"journal":["Brain : a journal of neurology"],"pubmed_title":["S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway."],"pmcid":["PMC3501971"],"funding_grant_id":["WT080782MF"],"pubmed_authors":["Mustafa S","Maetzler W","Sathe K","Lang JD","Martin HL","Teismann P","Schulte C","Berg D","Synofzik M","Mounsey RB","Fleckenstein C","Vukovic Z","Itohara S"],"additional_accession":[]},"is_claimable":false,"name":"S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.","description":"Parkinson's disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. S100B is a calcium-binding protein expressed in, and secreted by, astrocytes. There is increasing evidence that S100B acts as a cytokine or damage-associated molecular pattern protein not only in inflammatory but also in neurodegenerative diseases. In this study, we show that S100B protein levels were higher in post-mortem substantia nigra of patients with Parkinson's disease compared with control tissue, and cerebrospinal fluid S100B levels were higher in a large cohort of patients with Parkinson's disease compared with controls. Correspondingly, mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine showed upregulated S100B mes","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Nov","modification":"2026-05-02T09:21:47.625Z","creation":"2025-07-09T03:05:13.908Z"},"accession":"S-EPMC3501971","cross_references":{"pubmed":["23169921"],"doi":["10.1093/brain/aws250"]}}